| Citation: |
MAO Mingyi, JIANG Fang, XIANG Yang. Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 157-162. DOI: 10.12290/xhyxzz.2024-0135
|
Gestational trophoblastic neoplasia (GTN) patients can be classified into low-risk and high-risk patients based on the International Federation of Gynecology and Obstetrics(FIGO) staging and scoring system. High-risk patients have a higher risk of resistance to single-agent chemotherapy and require combination chemotherapy. Even worse, there are some high-risk patients who develop resistance to combination chemotherapy or experience recurrence after cure. These patients exhibit strong heterogeneity and pose significant challenges to subsequent treatment, thus attracting considerable attention in recent years. Therefore, this article aims to review the risk factors and treatment strategies for high-risk resistant and recurrent GTN patients, in order to provide a basis for early identification of high-risk patients and their precise treatment.
| [1] |
中国抗癌协会妇科肿瘤专业委员会. 妊娠滋养细胞疾病诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 520-532.
Gynecological Oncology Professional Committee of China Anti Cancer Association. Diagnosis and treatment guidelines for gestational trophoblastic diseases (2021 edition)[J]. China Oncol, 2021, 31(6): 520-532.
|
| [2] |
Kohorn E I. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment[J]. Int J Gynecol Cancer, 2001, 11(1): 73-77. DOI: 10.1136/ijgc-00009577-200101000-00011
|
| [3] |
Ngan H Y S, Seckl M J, Berkowitz R S, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update[J]. Int J Gynaecol Obstet, 2021, 155(S1): 86-93. DOI: 10.1002/ijgo.13877
|
| [4] |
Escobar P F, Lurain J R, Singh D K, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy[J]. Gynecol Oncol, 2003, 91(3): 552-557. DOI: 10.1016/j.ygyno.2003.08.028
|
| [5] |
Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2006, 16(3): 1432-1438. DOI: 10.1136/ijgc-00009577-200605000-00074
|
| [6] |
Li Y, Kong Y J, Wan X R, et al. Results with floxuridine, actinomycin D, etoposide, and vincristine in gestational trophoblastic neoplasias with international federation of gynecology and obstetrics scores ≥5[J]. Oncologist, 2021, 26(12): e2209-e2216. DOI: 10.1002/onco.13943
|
| [7] |
Jareemit N, Therasakvichya S, Freitas F, et al. EMACO for treatment of gestational trophoblastic neoplasia: a multina-tional multicenter study[J]. Gynecol Oncol, 2023, 170: 114-122. DOI: 10.1016/j.ygyno.2022.12.020
|
| [8] |
Yang J J, Xiang Y, Wan X R, et al. Primary treatment of stage Ⅳ gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): a report based on our 10-year clinical experiences[J]. Gynecol Oncol, 2016, 143(1): 68-72. DOI: 10.1016/j.ygyno.2016.07.099
|
| [9] |
Kong Y J, Zong L J, Cheng H Y, et al. Management and risk factors of recurrent gestational trophoblastic neoplasia: an update from 2004 to 2017[J]. Cancer Med, 2020, 9(7): 2590-2599. DOI: 10.1002/cam4.2901
|
| [10] |
Mao Y Y, Wan X Y, Lv W G, et al. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen[J]. Int J Gynaecol Obstet, 2007, 98(1): 44-47. DOI: 10.1016/j.ijgo.2007.03.037
|
| [11] |
Lu W G, Ye F, Shen Y M, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients[J]. Int J Gynecol Cancer, 2008, 18(2): 357-362. DOI: 10.1111/j.1525-1438.2007.00999.x
|
| [12] |
Wang M, Shen L N, Xu X H, et al. Real-world study of cisplatin, etoposide, and bleomycin chemotherapy regimen in gestational trophoblastic neoplasia[J]. Biomed Res Int, 2021, 2021: 6661698. DOI: 10.1155/2021/6661698
|
| [13] |
Wang J, Short D, Sebire N J, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE)[J]. Ann Oncol, 2008, 19(9): 1578-1583. DOI: 10.1093/annonc/mdn181
|
| [14] |
Feng F, Xiang Y, Wan X, et al. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia[J]. Ann Oncol, 2011, 22(7): 1588-1594. DOI: 10.1093/annonc/mdq649
|
| [15] |
Veras E, Kurman R J, Wang T L, et al. PD-L1 expression in human placentas and gestational trophoblastic diseases[J]. Int J Gynecol Pathol, 2017, 36(2): 146-153. DOI: 10.1097/PGP.0000000000000305
|
| [16] |
Bolze P A, Patrier S, Massardier J, et al. PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and Independent of clinical outcomes[J]. Int J Gynecol Cancer, 2017, 27(3): 554-561. DOI: 10.1097/IGC.0000000000000892
|
| [17] |
Huang M, Pinto A, Castillo R P, et al. Complete serologic response to pembrolizumab in a Woman with chemoresistant metastatic choriocarcinoma[J]. J Clin Oncol, 2017, 35(27): 3172-3174. DOI: 10.1200/JCO.2017.74.4052
|
| [18] |
Ghorani E, Kaur B, Fisher R A, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia[J]. Lancet, 2017, 390(10110): 2343-2345. DOI: 10.1016/S0140-6736(17)32894-5
|
| [19] |
You B, Bolze P A, Lotz J P, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: cohort B of the TROPHIMMUN phase 2 trial[J]. Gynecol Oncol, 2023, 168: 62-67. DOI: 10.1016/j.ygyno.2022.11.005
|
| [20] |
Cheng H Y, Zong L J, Kong Y J, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial[J]. Lancet Oncol, 2021, 22(11): 1609-1617. DOI: 10.1016/S1470-2045(21)00460-5
|
| [21] |
Wang X Y, Cang W, Liu X M, et al. Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study[J]. EClinicalMedicine, 2023, 59: 101974. DOI: 10.1016/j.eclinm.2023.101974
|
| [22] |
Hennah L, Seckl M, Ghorani E. Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy[J]. Int J Gynecol Cancer, 2023, 33(3): 414-419. DOI: 10.1136/ijgc-2022-003771
|
| [23] |
Doumplis D, Al-Khatib K, Sieunarine K, et al. Short communication: a review of the management by hysterectomy of 25 cases of gestational trophoblastic tumours from March 1993 to January 2006[J]. BJOG, 2007, 114(9): 1168-1171. DOI: 10.1111/j.1471-0528.2007.01347.x
|
| [24] |
Fang J, Wang S, Han X B, et al. Role of adjuvant hysterectomy in management of high-risk gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2012, 22(3): 509-514. DOI: 10.1097/IGC.0b013e31823f88e2
|
| [25] |
Sugrue R, Foley O, Elias K M, et al. Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease[J]. Gynecol Oncol, 2021, 160(2): 445-449. DOI: 10.1016/j.ygyno.2020.11.022
|
| [26] |
Feng F Z, Xiang Y, Li L, et al. Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neo-plasia[J]. Gynecol Oncol, 2009, 113(3): 312-315. DOI: 10.1016/j.ygyno.2009.02.025
|
| [27] |
Cao Y, Xiang Y, Feng F Z, et al. Surgical resection in the management of pulmonary metastatic disease of gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2009, 19(4): 798-801. DOI: 10.1111/IGC.0b013e3181a3d014
|
| [28] |
Kanis M J, Lurain J R. Pulmonary resection in the management of high-risk gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2016, 26(4): 796-800. DOI: 10.1097/IGC.0000000000000670
|
| [29] |
Zhao L, Qin Y Z, Ma D J, et al. Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: a retrospective study[J]. Gynecol Oncol, 2022, 167(1): 37-41. DOI: 10.1016/j.ygyno.2022.07.030
|
| [30] |
Kong Y J, Wang W D, Lin J K, et al. Management and predictors of treatment failure in patients with chemo-resistant/relapsed gestational trophoblastic neoplasia with lung metastasis[J]. J Clin Med, 2022, 11(24): 7270. DOI: 10.3390/jcm11247270
|
| [31] |
Manchana T, Ittiwut C, Mutirangura A, et al. Targeted therapies for rare gynaecological cancers[J]. Lancet Oncol, 2010, 11(7): 685-693. DOI: 10.1016/S1470-2045(09)70368-7
|
| [32] |
Worley M J, Elias K M, Horowitz N S, et al. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: a case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute[J]. Gynecol Oncol, 2018, 148(1): 5-11. DOI: 10.1016/j.ygyno.2017.11.029
|
| [1] | ZHANG Zuyu, WEI Hong, LIU Qian, WANG Yaoqiang, FAN Xueyan, LUO Ruiying, LUO Changjiang. Establishment of a LASSO-Logistic Regression-based Risk Prediction Model for Early Recurrence of Siewert Ⅱ/Ⅲ Adenocarcinoma of Esophagogastric Junction Post-Surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 604-615. DOI: 10.12290/xhyxzz.2023-0502 |
| [2] | ZHANG Zuyu, WEI Hong, LIU Qian, WANG Yaoqiang, FAN Xueyan, LUO Ruiying, LUO Changjiang. Establishment of a LASSO Regression-Based Risk Prediction Model for Early Recurrence of SiewertⅡ/Ⅲ Adenocarcinoma of Esophagogastric Junction Post-Surgery[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/j.issn.1674-9081.2023-0502 |
| [3] | QU Yang, ZHANG Yanna, ZHOU Yidong, SUN Qiang. Application of 21-gene Recurrence Score in Hormone Receptor Positive Breast Cancer Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1274-1281. DOI: 10.12290/xhyxzz.2023-0226 |
| [4] | LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271 |
| [5] | LIU Xiaohan, JIN Hongzhong. Risk Factors and Pathogenesis of the Recurrence of Psoriasis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 308-314. DOI: 10.12290/xhyxzz.2021-0367 |
| [6] | ZHANG Gumuyang, XU Lili, MAO Li, LI Xiuli, JIN Zhengyu, SUN Hao. CT-based Radiomics to Predict Recurrence of Bladder Cancer after Resection in One Year: A Preliminary Study[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 698-704. DOI: 10.12290/xhyxzz.2021-0511 |
| [7] | LIU Yanting, ZHANG Lu, CHEN Miao, ZHANG Yan, WEI Chong, PAN Boju, ZHAO Jiawei. A Case of Small B-cell Lymphocytic Lymphoma Diagnosed One Year after Evans Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 423-426. DOI: 10.12290/xhyxzz.20200063 |
| [8] | Man-man XU, Yun XU. Recurrent Ischemic Stroke[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 285-288. DOI: 10.3969/j.issn.1674-9081.2018.03.018 |
| [10] | Yong-sheng YANG, Mei-fen ZHANG, Zeng-yuan ZHUANG. Survey on the Causes of Uveitis Recurrence[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(2): 150-153. DOI: 10.3969/j.issn.1674-9081.2013.02.014 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: